These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 4039077

  • 1. Studies on the influence of reactants and buffer environment on clot lysis induced by human plasminogen activators.
    Westlund LE, Andersson LO.
    Thromb Res; 1985 Jan 01; 37(1):213-23. PubMed ID: 4039077
    [Abstract] [Full Text] [Related]

  • 2. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V, Pannell R.
    Thromb Res; 1986 Oct 15; 44(2):217-28. PubMed ID: 3097872
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V, Pannell R.
    Thromb Haemost; 1987 Jun 03; 57(3):372-3. PubMed ID: 3116707
    [No Abstract] [Full Text] [Related]

  • 7. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M, Zenker M, Klinge J, Keuper H, Harms D.
    J Pediatr Hematol Oncol; 1995 Aug 03; 17(3):260-4. PubMed ID: 7620925
    [Abstract] [Full Text] [Related]

  • 8. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH, Rijken DC.
    Thromb Haemost; 2004 Mar 03; 91(3):473-9. PubMed ID: 14983222
    [Abstract] [Full Text] [Related]

  • 9. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM, Dosne AM, Kher A, Samama M.
    Thromb Haemost; 1989 Nov 24; 62(3):923-6. PubMed ID: 2556812
    [Abstract] [Full Text] [Related]

  • 10. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R, Black J, Gurewich V.
    J Clin Invest; 1988 Mar 20; 81(3):853-9. PubMed ID: 2963831
    [Abstract] [Full Text] [Related]

  • 13. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
    Kajimoto Y, Ohta T, Kuroiwa T.
    Neurosurgery; 1997 Mar 20; 40(3):572-7. PubMed ID: 9055298
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
    Trübestein G, Popov S, Wolf H, Welzel D.
    Haemostasis; 1987 Mar 20; 17(4):238-44. PubMed ID: 2442078
    [Abstract] [Full Text] [Related]

  • 16. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D.
    Thromb Haemost; 1992 Aug 03; 68(2):170-9. PubMed ID: 1412163
    [Abstract] [Full Text] [Related]

  • 17. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R, Li S, Gurewich V.
    J Thromb Thrombolysis; 2017 Aug 03; 44(2):210-215. PubMed ID: 28600623
    [Abstract] [Full Text] [Related]

  • 18. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
    Trusen B, Ries M, Zenker M, Rauh M, Beinder E, Keuper H, Harms D.
    Semin Thromb Hemost; 1998 Aug 03; 24(6):599-604. PubMed ID: 10066156
    [Abstract] [Full Text] [Related]

  • 19. Activation of the fibrinolytic system.
    Robison AK, Collen D.
    Cardiol Clin; 1987 Feb 03; 5(1):13-9. PubMed ID: 3103919
    [Abstract] [Full Text] [Related]

  • 20. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A, Ling RJ, Sutton PM, Griffiths B, Riley PA, Atkinson T.
    Thromb Haemost; 1985 Apr 22; 53(2):200-3. PubMed ID: 4040659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.